Trials / Conditions / Acute Myeloblastic Leukemia

Acute Myeloblastic Leukemia

20 registered clinical trials studyying Acute Myeloblastic Leukemia — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients NCT07250217	Groupe Hospitalier de la Region de Mulhouse et Sud Alsace	N/A
Recruiting	Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematolog NCT07016165	Gadjah Mada University	Phase 4
Completed	Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia NCT05499611	University Hospital, Bordeaux	—
Completed	Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCT NCT05696457	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz	N/A
Completed	Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 NCT04452604	French Innovative Leukemia Organisation	—
Completed	Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia NCT04082286	Great Ormond Street Hospital for Children NHS Foundation Trust	Phase 1
Unknown	Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia NCT01966497	Assistance Publique - Hôpitaux de Paris	—
Completed	Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia NCT01435343	PETHEMA Foundation	Phase 1 / Phase 2
Completed	Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leuk NCT01611116	Goethe University	Phase 2
Completed	Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft NCT03280290	University Hospital, Lille	N/A
Completed	Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen NCT01457885	University of Michigan Rogel Cancer Center	Phase 2
Unknown	RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic NCT01307241	National Institute of Cancerología	—
Unknown	PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years NCT01296178	PETHEMA Foundation	N/A
Completed	LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO NCT01041040	PETHEMA Foundation	Phase 4
Completed	Natural Killer Index From Hematopoietic Stem Cell Graft NCT00435864	Nantes University Hospital	N/A
Completed	Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children NCT00552825	Sheba Medical Center	—
Completed	Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant NCT00354120	Gruppo Italiano Trapianto di Midollo Osseo	Phase 2 / Phase 3
Completed	Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients NCT00504920	M.D. Anderson Cancer Center	—
Completed	Treatment of Acute Myeloblastic Leukemia in Younger Patients NCT00390715	PETHEMA Foundation	—
Completed	SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Mye NCT00487448	PETHEMA Foundation	Phase 4